Aventis Pharma S.a.

Sanofi-a Ventis Deutschland Gmbh

Sanofi

Novexel

Novexel Sa

Baptiste Ronan

Eric Bacque

Fabrice Viviani

Pascal Desmazeau

Michel Tabart

Serge Mignani

Jean-Christophe Carry

Jean-Claude Barriere

Antony Bigot

Frank Halley

Catherine Souaille

Jean-Philippe Letallec

Heinz-Werner Kleemann

Youssef El-Ahmad

Bruno Filoche-Romme

Maurice Brollo

Gilbert Marciniak

Youssef El Ahmad

Bertrand Vivet

Arielle Genevois-Borella

Jean Bouquerel

Jean-Luc Malleron

Corinne Terrier

Yves Ribeill

Stefanie Keil

Armin Hofmeister

Wolfgang Wendler

Laurent Schio

Daniel Achard

Maike Glien

Serge Grisoni

Vincent Leroy

Karl Andreas Karlsson

Jean-Pierre Leconte

Patrick Bernardelli

Annie Clauss

Andre Zimmermann

Hans-Ludwig Schaefer

Jochen Goerlitzer

Marcel Patek

Michel Cheve

Gilles Doerflinger

Daniel Gerard McGarry

Martin Smrcina

Herv&eacute; Bouchard

Anil Nair

Hervé Minoux

Jean-Paul Martin

Anke Steinmetz

Alain Commer&ccedil;on

Karen Chandross

Kirsten Bjergarde

Jean Merrill

Emmanuel Conseiller

Antonio Ugolini

Guy Pantel

Eric Bacqué

Mark Dodson

Jacques Clement

François Clerc

Bruno Filoche-Rommé

Claude E Barberis

Nicolas Muzet

Dominique Barbalat-Damour

Véronique Zerr

Jean Bououerel

G&eacute;rard Puchault

Martha Ackerman-Berrier

Yves Janin

Jerome Arigon

Axel Ganzhorm

Romain Combet

Florence Durand

Jean-Robert Labrosse

Youssef El-ahmad

Jérome Arigon

Bruno Filoche-RommÉ

André Zimmermann

The invention relates to the novel products of formula (I): with p, q=0, 1 or 2; R1=phenyl, pyridyl; &#x2014;(CH)&#x2014;Ra; alkylene; cycloalkyl; heterocycloalkyl; alkyl; &#x2014;SO&#x2014;Rb; &#x2014;CO&#x2014;Re; m=1 or 2; Ra=aryl, heteroaryl, &#x2014;CO-cycloalkyl, &#x2014;CO-heterocycloalkyl, &#x2014;CO&#x2014;Rb, &#x2014;C(Rb)&#x2550;N&#x2014;ORc, &#x2014;CORd, &#x2014;CONRxRy; Rb=alkyl, aryl, heteroaryl; Rc=H, alkyl; Rd=alkyl, cycloalkyl; Re=alkyl, cycloalkyl, aryl, heteroaryl; NRxRy with Rx,Ry=H, alkyl, cycloalkyl, alkoxy, phenyl, or form with N a ring with optionally O, N; R2, R3=H, alkyl, CF, or form with C a ring with optionally O, S and N; R4=H, F, Cl, CHor CN; the morpholine is substituted with Me, and optionally substituted with F, OH; or is and the isomer of configuration R,R these products being in all the isomer forms and the salts, as medicaments, in particular as anticancer medicaments.

2,3-dihydro-1h-imidazo{1,2-a}pyrimidin-5-one and this 1,2,3,4-tetrahydropyrimido{1,2-a}pyrimidin-6-one derivatives comprising a substituted morpholine, preparation thereof and pharmaceutical use thereof

The invention relates to the novel products of formula (I) with p, q=0, 1 or 2; R1=phenyl, pyridyl; &#x2014;(CH)&#x2014;Ra; alkylene; cycloalkyl; heterocycloalkyl; alkyl; &#x2014;SO&#x2014;Rb; &#x2014;CO&#x2014;Re; m=1 or 2; Ra=aryl, heteroaryl, &#x2014;CO-cycloalkyl, &#x2014;CO-heterocycloalkyl, &#x2014;CO&#x2014;Rb, &#x2014;C(Rb)&#x2550;N&#x2014;ORc, &#x2014;CO 2 Rd, &#x2014;CONRxRy; Rb=alkyl, aryl, heteroaryl; Rc=H, alkyl; Rd=alkyl, cycloalkyl; Re=alkyl, cycloalkyl, aryl, heteroaryl; NRxRy with Rx,Ry=H, alkyl, cycloalkyl, alkoxy, phenyl, or form with N a ring with optionally O, N; R2, R3=H, alkyl, CF 3, or form with C a ring with optionally O, S and N; R4=H, F, Cl, CHor CN; the morpholine is substituted with Me, and optionally substituted with F, OH; or is (Formula 1a) and the isomer of configuration R,R (Formula 1b) these products being in all the isomer forms and the salts, as medicaments, in particular as anticancer medicaments. 

2,3-dihydro-1H-imidazo{1,2-a}pyrimidin-5-one and this 1,2,3,4-tetrahydropyrimido{1,2-a}pyrimidin-6-one derivatives comprising a substituted morpholine, preparation thereof and pharmaceutical use thereof

The invention relates to novel pyrimidinone-based heterocyclic compounds which are parasite growth inhibitors, having the general formula (I) in which Y is a morpholine chosen from three bridged morpholines, L is a bond or a linker, n=0 or 1 and Ris a methyl group when n=0 and a hydrogen atom when n=1. Process for the preparation thereof and therapeutic use thereof. 

Pyrimidinone derivatives as antimalarial agents

The invention relates to compounds of the formula:  or their racemic, enantiomeric or diastereoisomeric isomers, or pharmaceutically acceptable salts of the compounds of formula I or the racemic, enantiomeric or diasteroisomeric isomers.

1,2,3,4-tetrahydro-pyrimido(1,2-a)pyrimidin-6-one derivatives, preparation thereof, and pharmaceutical use thereof

The invention relates to a product of formula (I) where R1, R2, R3, and R4 are as defined herein, the therapeutic use of the product, a process to make the product, and a pharmaceutical composition comprising the product.

2,3-dihydro-1H-imidazo(1,2-a)pyrimidin-5-one derivatives, preparation thereof, and pharmaceutical use thereof

The invention relates to novel products of formula (Ia) or (Ib): 

Pyrimidinone derivatives, preparation thereof and pharmaceutical use thereof

The present invention relates to imidazolone derivatives of formula (I) to methods of preparing such derivatives, intermediates thereto, pharmaceutical compositions comprising such derivatives, and methods of inhibiting protein kinase, and methods of treatment comprising administration of such derivatives.

Imidazolone derivatives, preparation thereof as drugs, pharmaceutical compositions, and use thereof as protein kinase inhibitors, in particular CDC7

The disclosure relates to compounds of formula (I): which modulate the activity of proteins, particularly kinases, and to compositions containing the same, and to the use thereof as medicaments, in particular as anticancer agents.

7-substituted aza-indazoles, compositions containing same, production method and use thereof

The disclosure relates to substituted pyrazolo-pyridines, compositions containing them, methods for the production thereof, and to their use as medicaments, in particular, as anticancer agents.

Substituted pyrazolopyridines, compositions containing them, method for the production thereof, and their use

The invention relates to compounds of formula (I): wherein Ra, R1, Ar, L, A, W, Y, and Z are as defined in the disclosure; to compositions containing them; and to the preparation and use thereof, in particular as anticancer agents.

Substituted pyrrolopyridines, compositions containing them, manufacturing process therefor and use thereof

Compounds of formula (I), wherein R1 and R3 have the meanings given in the description, said compounds being in all isomeric forms; and salts thereof; processes for the preparation of the compounds and intermediates; compositions containing them, and the use thereof as medicaments, particularly as anti-cancer agents.

Substituted thieno[2,3-c]pyrazoles, process for preparing them, compositions containing them, and use thereof

The invention relates to oxadiazolones and to their physiologically acceptable salts and physiologically functional derivatives showing peroxisome proliferator activator receptor (PPAR) delta agonist activity comprising compounds of formula I, in which the R1-R7 substituents as well as the U, V, W, X Y and z radicals are as defined herein, and their physiologically acceptable salts and processes for their preparation. The compounds are suitable for the treatment and/or prevention of disorders of fatty acid metabolism and glucose utilization disorders as well as of disorders in which insulin resistance is involved; neurodegenerative diseases and/or demyelinating disorders of the central and peripheral nervous systems and/or neurological diseases involving neuro-inflammatory processes and/or other peripheral neuropathies.

Oxadiazolones and derivatives thereof as peroxisome proliferator-activated receptor (PPAR) delta agonists

The present invention relates to 3-guanidinocarbonyl-1-heteroaryl-indole derivatives, pharmaceutical compositions comprising such derivatives, methods of treatment comprising administering such derivatives, and processes for their preparation.

3-guanidinocarbonyl-1-heteroaryl-indole derivatives, preparation process, their use as medicaments, and pharmaceutical compositions comprising them

The disclosure concerns substituted pyrroles of formula (I): wherein A, L, Ar, R1, R2, R5, and Ra are as defined in the disclosure, compositions containing the same, methods for making the same and uses thereof, in particular as anti-cancer agents.

Substituted pyrroles, compositions containing same, method for making same and use thereof

The present invention relates to the novel isoindolone derivatives of the formula I in which R1 to R6 have the meanings stated in the claims. The inventive compounds are suitable as antiarrhythmic medicaments with a cardioprotective component for infarction prophylaxis and infarction treatment and for the treatment of angina pectoris. They also inhibit in a preventive manner the pathophysiological processes associated with the development of ischemia-induced damage, in particular in the triggering of ischemia-induced cardiac arrhythmias and of heart failure.

Isoindolone derivatives, preparation process and intermediates of this process, their use as medicaments, and pharmaceutical compositions comprising them

Growing community of inventors

Clamart, France

Baptiste Ronan